Ocugen (OCGN) Short term Debt (2014 - 2026)

Ocugen (OCGN) posted Short term Debt of $5.0 million for Q1 2026, up 300.4% on a QoQ basis from $1.2 million in Q4 2025.

Ocugen (OCGN) Short term Debt (2014 - 2026) Analysis & Trends

Ocugen's Short term Debt history runs 12 years deep, the most recent figure standing at $5.0 million for Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (changed N/A YoY) and the FY2025 annual result came in at $1.2 million, down 5.73% from the prior year.
Short term Debt was $5.0 million for Q1 2026 at Ocugen, up from $1.2 million in the prior quarter.
Across five years, Short term Debt topped out at $5.0 million in Q1 2026 and bottomed at $1.2 million in Q4 2025.
A 4-year average of $1.7 million and a median of $1.3 million in 2024 frame the typical range for Short term Debt.
Annual changes were most pronounced in 2024 — Short term Debt rose 3.18% — and 2025, when it slipped 5.73%.
Ocugen's Short term Debt stood at $1.3 million in 2023, then gained by 3.92% to $1.3 million in 2024, then fell by 5.73% to $1.2 million in 2025, then jumped by 300.4% to $5.0 million in 2026.
Business Quant data shows OCGN's Short term Debt at $5.0 million in Q1 2026, $1.2 million in Q4 2025, and $1.3 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Ocugen	63.79 Mn	63.79 Mn	-

Download Data